

Zydus receives approval for Tamsulosin capsules

Ahmedabad, 28 April 2010

Zydus Cadila has received an approval from the USFDA to market Tamsulosin capsules, 0.4 mg. Tamsulosin falls in the urology segment and is indicated for the treatment of Benign Prostatic Hyperplasia (BPH).

The estimated sales in 2009 as per NDC for Tamsulosin capsules was USD 2.79 bn.

The group now has 54 approvals and has so far filed 106 ANDAs since the commencement of filing process in FY 2003-04.
